Lipella Pharmaceuticals (LIPO) Proxy Filing summary

Executive summary

• A special meeting of stockholders was convened on December 6, 2024, but was adjourned due to lack of quorum and rescheduled for December 20, 2024.

• Valid proxies submitted for the original meeting remain valid for the reconvened meeting unless changed or revoked before voting.

Voting matters and shareholder proposals

• Stockholders will be able to vote at the reconvened meeting as disclosed in the Definitive Proxy Statement filed on November 12, 2024.

Shareholder rights and capital structure

• Common stock is registered and traded on the Nasdaq Stock Market under the symbol LIPO.

• The company is classified as an emerging growth company under SEC rules.